Keros Therapeutics, Inc. (KROS) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$243.9M

Net Income/Loss (FY2025)

$87.0M

Total Assets (FY2025)

$338.0M

Total Equity (FY2025)

$303.1M

Cash Flows from Operating Activities (FY2025)

$107.5M

Source: Keros Therapeutics, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.